PED mediates AKT-dependent chemoresistance in human breast cancer cells.

Killing of tumor cells by cytotoxic therapies, such as chemotherapy or gamma-irradiation, is predominantly mediated by the activation of apoptotic pathways. Refractoriness to anticancer therapy is often due to a failure in the apoptotic pathway. The mechanisms that control the balance between survival and cell death in cancer cells are still largely unknown. Tumor cells have been shown to evade death signals through an increase in the expression of antiapoptotic molecules or loss of proapoptotic factors. We aimed to study the involvement of PED, a molecule with a broad antiapoptotic action, in human breast cancer cell resistance to chemotherapeutic drugs-induced cell death. We show that human breast cancer cells express high levels of PED and that AKT activity regulates PED protein levels. Interestingly, exogenous expression of a dominant-negative AKT cDNA or of PED antisense in human breast cancer cells induced a significant down-regulation of PED and sensitized cells to chemotherapy-induced cell death. Thus, AKT-dependent increase of PED expression levels represents a key molecular mechanism for chemoresistance in breast cancer.

[1]  W. Liu,et al.  Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.

[2]  D. Weaver,et al.  The TNM staging system and breast cancer. , 2003, The Lancet. Oncology.

[3]  J. Boyd,et al.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. , 1997, Cancer research.

[4]  C. Eng,et al.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.

[5]  Baljit Singh,et al.  Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus , 1998, Genes, chromosomes & cancer.

[6]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[7]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Beguinot,et al.  Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Death-inducing Signaling Complex and Its Modulation by c-FLIP and PED/PEA-15 in Glioma Cells* , 2002, The Journal of Biological Chemistry.

[9]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[10]  Tak W. Mak,et al.  Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.

[11]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[12]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[13]  G. Condorelli,et al.  Protein Kinase B/Akt Binds and Phosphorylates PED/PEA-15, Stabilizing Its Antiapoptotic Action , 2003, Molecular and Cellular Biology.

[14]  M. Kampa,et al.  Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  J. Tschopp,et al.  Inhibition of fas death signals by FLIPs. , 1998, Current opinion in immunology.

[16]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[17]  J. Testa,et al.  AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival , 2002, Oncogene.

[18]  R. Karas,et al.  17&bgr;-Estradiol Reduces Cardiomyocyte Apoptosis In Vivo and In Vitro via Activation of Phospho-Inositide-3 Kinase/Akt Signaling , 2004, Circulation research.

[19]  J. Girault,et al.  Endothelin Induces a Calcium‐Dependent Phosphorylation of PEA‐15 in Intact Astrocytes: Identification of Ser104 and Ser116 Phosphorylated, Respectively, by Protein Kinase C and Calcium/Calmodulin Kinase II In Vitro , 1998, Journal of neurochemistry.

[20]  H. Feilotter,et al.  Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma , 1999, British Journal of Cancer.

[21]  J. Glowinski,et al.  Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. , 1993, The Journal of biological chemistry.

[22]  B. Li,et al.  A novel conditional Akt ‘survival switch’ reversibly protects cells from apoptosis , 2002, Gene Therapy.

[23]  J. Tschopp,et al.  Inhibition of Death Receptor Signaling by Flice-Inhibitory Protein as a Mechanism for Immune Escape of Tumors , 1999, The Journal of experimental medicine.

[24]  Isabelle Callebaut,et al.  The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. , 2003, Biochemical pharmacology.

[25]  P. Depowski,et al.  Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer , 2001, Modern Pathology.

[26]  E. Liu,et al.  Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. , 2001, Cancer research.

[27]  J. Glowinski,et al.  Knock-Out of the Neural Death Effector Domain Protein PEA-15 Demonstrates That Its Expression Protects Astrocytes from TNFα-Induced Apoptosis , 1999, The Journal of Neuroscience.

[28]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[29]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[30]  F. Andreozzi,et al.  PED/PEA‐15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus , 1998, The EMBO journal.

[31]  L. Ailles,et al.  Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.

[32]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[33]  E. Jabs,et al.  Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. , 1994, Genomics.

[34]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[35]  J. Ross,et al.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[37]  D. Vaux,et al.  Alterations in the apoptotic machinery and their potential role in anticancer drug resistance , 2003, Oncogene.

[38]  M. Campiglio,et al.  Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.

[39]  Erwin G. Van Meir,et al.  Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. , 2001, Cancer research.

[40]  W. Kuo,et al.  Assignment of HMAT1, the human homolog of the murine mammary transforming gene (MAT1) associated with tumorigenesis, to 1q21.1, a region frequently gained in human breast cancers. , 1997, Genomics.

[41]  S. Miyamoto,et al.  Identification of a mammary transforming gene (MAT1) associated with mouse mammary carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Krammer,et al.  Death receptors in chemotherapy and cancer , 2004, Oncogene.

[43]  T. Tsukamoto,et al.  Expression of MAT1/PEA-15 mRNA isoforms during physiological and neoplastic changes in the mouse mammary gland. , 2000, Cancer letters.

[44]  J. Ting,et al.  MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis* , 2000, The Journal of Biological Chemistry.

[45]  J. Ting,et al.  Paclitaxel (Taxol)-induced Gene Expression and Cell Death Are Both Mediated by the Activation of c-Jun NH2-terminal Kinase (JNK/SAPK)* , 1998, The Journal of Biological Chemistry.

[46]  K. Tanabe,et al.  The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). , 2002, Oncology reports.

[47]  G. Condorelli,et al.  PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis , 1999, Oncogene.

[48]  A. Musti,et al.  Multiple Members of the Mitogen-activated Protein Kinase Family Are Necessary for PED/PEA-15 Anti-apoptotic Function* , 2002, The Journal of Biological Chemistry.

[49]  G. Mills,et al.  Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. , 1992, Cancer research.